The results indicated that, in stages 3 and 4, the ESR1 gene expression levels were highly expressed in all invasive breast carcinoma patients; however, in subtypes such as Her2, Luminal A, and Luminal B, they were only expressed in stage 4. Here, ERBB2 is linked to invasive breast carcinoma.